Finch Therapeutics has raised $53 million in Series C financing to support the clinical development of its microbial therapies, including CP101, an oral microbiome capsule for recurrent Clostridioides difficile infection.
The capsule — known as a Full-Spectrum Microbiota therapy — is currently being tested in the company’s PRISM3 trial for the prevention of CDI. The FDA granted Fast Track designation to CP101 last year and a breakthrough designation early in 2019.
According to a press release issued by the company, Finch hopes to expand its microbiome therapies to inflammatory

Source link